|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rubin KM and Lawrence DP: Your patient
with melanoma: Staging, prognosis, and treatment. Oncology
(Williston Park). 23(Suppl 8): 13–21. 2009.
|
|
3
|
Grossman D and Altieri DC: Drug resistance
in melanoma: Mechanisms, apoptosis, and new potential therapeutic
targets. Cancer Metastasis Rev. 20:3–11. 2001. View Article : Google Scholar
|
|
4
|
La Porta CA: Mechanism of drug sensitivity
and resistance in melanoma. Curr Cancer Drug Targets. 9:391–397.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexandrescu DT, Ichim TE, Riordan NH,
Marincola FM, Di Nardo A, Kabigting FD and Dasanu CA: Immunotherapy
for melanoma: current status and perspectives. J Immunother.
33:570–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Korn EL, Liu P-Y, Lee SJ, Chapman JA,
Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer
EA, et al: Meta-analysis of phase II cooperative group trials in
metastatic stage IV melanoma to determine progression-free and
overall survival benchmarks for future phase II trials. J Clin
Oncol. 26:527–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gajewski TF: Identifying and overcoming
immune resistance mechanisms in the melanoma tumor
microenvironment. Clin Cancer Res. 12:2326s–2330s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coles AH and Jones SN: The ING gene family
in the regulation of cell growth and tumorigenesis. J Cell Physiol.
218:45–57. 2009. View Article : Google Scholar
|
|
9
|
Gunduz M, Gunduz E, Rivera RS and
Nagatsuka H: The inhibitor of growth (ING) gene family: Potential
role in cancer therapy. Curr Cancer Drug Targets. 8:275–284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiseki M, Nagashima M, Pedeux RM,
Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y,
Appella E, Yokota J, et al: p29ING4 and p28ING5 bind to p53 and
p300, and enhance p53 activity. Cancer Res. 63:2373–2378.
2003.PubMed/NCBI
|
|
11
|
Li J, Martinka M and Li G: Role of ING4 in
human melanoma cell migration, invasion and patient survival.
Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friesen C, Herr I, Krammer PH and Debatin
K-M: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in
drug-induced apoptosis in leukemia cells. Nat Med. 2:574–577. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hahne M, Rimoldi D, Schröter M, Romero P,
Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard
D, et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand:
Implications for tumor immune escape. Science. 274:1363–1366. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bullani RR, Wehrli P, Viard-Leveugle I,
Rimoldi D, Cerottini JC, Saurat JH, Tschopp J and French LE:
Frequent downregulation of Fas (CD95) expression and function in
melanoma. Melanoma Res. 12:263–270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Helmbach H, Rossmann E, Kern MA and
Schadendorf D: Drug-resistance in human melanoma. Int J Cancer.
93:617–622. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ekmekcioglu S, Okcu MF, Colome-Grimmer MI,
Owen-Schaub L, Buzaid AC and Grimm EA: Differential increase of Fas
ligand expression on metastatic and thin or thick primary melanoma
cells compared with interleukin-10. Melanoma Res. 9:261–272. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Cai L, Liang M, Wang Y, Yang J and
Zhao Y: ING4 induces cell growth inhibition in human lung
adenocarcinoma A549 cells by means of Wnt-1/β-catenin signaling
pathway. Anat Rec (Hoboken). 291:593–600. 2008. View Article : Google Scholar
|
|
18
|
Clay TM, Custer MC, Sachs J, Hwu P,
Rosenberg SA and Nishimura MI: Efficient transfer of a tumor
antigen-reactive TCR to human peripheral blood lymphocytes confers
anti-tumor reactivity. J Immunol. 163:507–513. 1999.PubMed/NCBI
|
|
19
|
Li X, Cai L, Chen H, Zhang Q, Zhang S,
Wang Y, Dong Y, Cheng H and Qi J: Inhibitor of growth 4 induces
growth suppression and apoptosis in glioma U87MG. Pathobiology.
76:181–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang QS, Li M, Zhang LY, Jin Y, Tong DD,
Yu Y, Bai J, Huang Q, Liu FL, Liu A, et al: Downregulation of ING4
is associated with initiation and progression of lung cancer.
Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Zhang Q, Cai L, Wang Y, Wang Q,
Huang X, Fu S, Bai J, Liu J, Zhang G, et al: Inhibitor of growth 4
induces apoptosis in human lung adenocarcinoma cell line A549 via
Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer
Res Clin Oncol. 135:829–835. 2009. View Article : Google Scholar
|
|
22
|
Garkavtsev I, Kozin SV, Chernova O, Xu L,
Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour
suppressor protein ING4 regulates brain tumour growth and
angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen JC, Unoki M, Ythier D, Duperray A,
Varticovski L, Kumamoto K, Pedeux R and Harris CC: Inhibitor of
growth 4 suppresses cell spreading and cell migration by
interacting with a novel binding partner, liprin α1. Cancer Res.
67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Yu L, Wang Y, Zhang Y, Wang Y and
Zhang G: Expression of tumor suppressor gene ING4 in ovarian
carcinoma is correlated with microvessel density. J Cancer Res Clin
Oncol. 138:647–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan FK-M, Luz NF and Moriwaki K:
Programmed necrosis in the cross talk of cell death and
inflammation. Annu Rev Immunol. 33:79–106. 2015. View Article : Google Scholar :
|
|
26
|
Chen G and Emens LA: Chemoimmunotherapy:
Reengineering tumor immunity. Cancer Immunol Immunother.
62:203–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hohlbaum AM, Moe S and Marshak-Rothstein
A: Opposing effects of transmembrane and soluble Fas ligand
expression on inflammation and tumor cell survival. J Exp Med.
191:1209–1220. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nagata S and Golstein P: The Fas death
factor. Science. 267:1449–1456. 1995. View Article : Google Scholar : PubMed/NCBI
|
